Beside stage and tumor size, the leading biomarkers that define breast cancer treatment recommendations are estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth-factor receptor 2 (HER2); histological grade; and in many countries, the Ki67 proliferation index [1]. This evidence concerns the gene MKI67 and neoplasm.